Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09UXP
|
||||
| Former ID |
DIB011493
|
||||
| Drug Name |
AZD-1744
|
||||
| Synonyms |
Dual CCR3/H-1 receptor antagonist (chronic obstructive pulmonary disease (COPD)), AstraZeneca
|
||||
| Indication | Asthma [ICD10:J45] | Discontinued in Phase 1 | [1] | ||
| Company |
AstraZeneca plc
|
||||
| Target and Pathway | |||||
| Target(s) | C-C chemokine receptor type 3 | Target Info | Modulator | [2] | |
| Histamine H1 receptor | Target Info | Modulator | [2] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| Chemokine signaling pathway | |||||
| Viral carcinogenesishsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL3 Signaling Pathway | ||||
| PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathwayP04385:Histamine H1 receptor mediated signaling pathway | ||||
| Reactome | Chemokine receptors bind chemokines | ||||
| G alpha (i) signalling eventsR-HSA-390650:Histamine receptors | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| IL1 and megakaryotyces in obesity | |||||
| IL-3 Signaling Pathway | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| IL-4 Signaling Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025772) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.